Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke and venous thrombosis.

Researchers developed an experimental anticoagulant, or blood thinner, that blocks the activity of a protein involved in the ...

Direct inhibition of thrombin may offer similar anticoagulant properties but also impact the underlying disease process. As we continue to gain experience and develop new DTIs, a new balance may ...

Thrombin is a serine protease whose specificity determines the fate of the blood coagulation cascade. The last in a chain of membrane-bound factors and cofactors (), thrombin cleaves plasma ...

The anticoagulant has been developed uses what we call supramolecular chemistry. This allows the two active molecules needed ...

The thrombin time assay is a versatile clinical assay used for screening fibrinogen related disorders and quantification of fibrin degradation products, as well as for detecting the presence of ...

To understand the pharmacology and mechanism of action of ximelagatran, a review of the formation and function of thrombin is warranted. [10] The generation of thrombin is limited under normal ...

A completely novel way to develop 'surpamolecules' for drug discovery could have application in immunotherapy as well as this breakthrough design for an anticoagulant with on-demand reversibility.

Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke and venous thrombosis.

After selling his previous firm, The Medicines Company, to Novartis for $9.7 billion, Clive Meanwell is on to his next ...

In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...